Compare Grab Holdings Ltd. (GRAB) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance

GRAB trades at $2.91, down 7.62% in the past 24 hours, with technical indicators showing bearish momentum. The company demonstrates strong fundamental improvement with revenue growing from $1.4B in 2022 to $3.37B in 2025 and achieving profitability with $268M net income. Recent developments include the $1.49B acquisition of Atome Financial and aggressive share repurchases, while management has shown confidence through significant insider buying.

GRAB presents a compelling turnaround story with accelerating revenue growth and recent profitability. The stock trades at reasonable valuations (P/E 27.09, P/S 3.65) with 92% analyst buy ratings. Key risks include integration challenges from the Atome acquisition and regional regulatory uncertainties in Southeast Asian markets.

Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.

The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.